These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 540479

  • 21. [Long-term therapy of type II and type IV hyperlipoproteinemia using beclobrate].
    Uglesić A, Ljachnicky N.
    Schweiz Rundsch Med Prax; 1988 Jul 05; 77(27-28):755-61. PubMed ID: 3041534
    [No Abstract] [Full Text] [Related]

  • 22. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L, Mingrone G, Ghirlanda G, Manna R, Rebuzzi A, Pala MA, Greco AV.
    Minerva Med; 1980 Feb 11; 71(4):273-8. PubMed ID: 7354946
    [Abstract] [Full Text] [Related]

  • 23. [Hypolipemic effects of 1-10(hydroxy-2 ethylthio) decane (LL1558), based on 77 cases of essential hyperlipidemia].
    Rouffy J, Loeper J.
    Therapie; 1972 Feb 11; 27(3):433-44. PubMed ID: 4570211
    [No Abstract] [Full Text] [Related]

  • 24. [Familial hypercholesterolemia. Screening, prevention and therapeutic possibilities].
    Vierucci A, Biadaioli R, De Martino M, Pratesi F, Novembre E, Morotti P.
    Minerva Pediatr; 1982 Apr 30; 34(8):325-36. PubMed ID: 7048049
    [No Abstract] [Full Text] [Related]

  • 25. [Hypolipemic property and myotoxic action of clofibrate in a case of nephrotic syndrome].
    Fabre J, Denizot M, Wildi E, Micheli H, Berthoud S.
    Schweiz Rundsch Med Prax; 1973 Jun 05; 62(23):732-7. PubMed ID: 4705828
    [No Abstract] [Full Text] [Related]

  • 26. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Jun 05; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 27. [Thiadenol in the short-term treatment of patients with blood lipid disorders].
    Di Stefano F, Patane S, Gatto A.
    Minerva Med; 1980 Mar 03; 71(8):567-74. PubMed ID: 7360386
    [Abstract] [Full Text] [Related]

  • 28. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias.
    Tuomilehto J, Salonen J, Kuuisto P, Virtamo J, Manninen V, Mälkönen M.
    Proc R Soc Med; 1976 Mar 03; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195
    [Abstract] [Full Text] [Related]

  • 29. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W, Schilling A, Calder D.
    Med Welt; 1980 Apr 04; 31(14):515-20. PubMed ID: 7374415
    [No Abstract] [Full Text] [Related]

  • 30. [Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia].
    Nikitin IuP, Slepchenko NV, Gratsianskiĭ NA, Nechaev AS, Syrkin AL, Poltavskaia MG, Sumarokov AV, Revazov AV.
    Ter Arkh; 2000 Apr 04; 72(12):7-10. PubMed ID: 11201841
    [Abstract] [Full Text] [Related]

  • 31. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J, Martorell J.
    Clin Ther; 1980 Apr 04; 3(4):234-41. PubMed ID: 7273061
    [Abstract] [Full Text] [Related]

  • 32. [Diet and drug therapy of hyperlipoproteinemia].
    Sirtori C.
    Minerva Med; 1975 Nov 21; 66(79):4184-5. PubMed ID: 1196507
    [No Abstract] [Full Text] [Related]

  • 33. [The management of hyperlipoproteinemia with Liproreduct].
    Fenster R.
    Ther Ggw; 1974 May 21; 113(5):813-24. PubMed ID: 4603893
    [No Abstract] [Full Text] [Related]

  • 34. [Pharmacological treatment of primary hyperlipoproteinemia].
    Ciświcka-Sznajderman M.
    Pol Tyg Lek; 1976 Feb 16; 31(7):289-91. PubMed ID: 768941
    [No Abstract] [Full Text] [Related]

  • 35. [Evaluation of the effects of tiadenol in various types of dyslipidemia].
    Saettone G, Cazzani E, Romanò M, Muzio L.
    Clin Ter; 1982 May 31; 101(4):387-93. PubMed ID: 7105643
    [No Abstract] [Full Text] [Related]

  • 36. Clinical importance of clofibrate induced increase of creatine kinase catalytic activity concentration in serum.
    Schneider J.
    J Clin Chem Clin Biochem; 1981 Aug 31; 19(8):539-40. PubMed ID: 7276838
    [Abstract] [Full Text] [Related]

  • 37. [Cross-over study of benfluorex and a hypolipemic agent in diet-resistant types IV and II b hyperlipemia (author's transl)].
    Graisely B, Cloarec M.
    Sem Hop; 1981 Aug 31; 56(25-28):1221-5. PubMed ID: 6256875
    [Abstract] [Full Text] [Related]

  • 38. [Rapid changes in blood lipid parameters induced by glucuronyl glucosamine glycan sulfate in obese diabetic and hyperlipidemia patients].
    Ferlito S, La Spina E, Fichera C, Cultrera E, Patanè M, Ciulla P.
    Arch Sci Med (Torino); 1982 Aug 31; 139(4):441-8. PubMed ID: 7168636
    [No Abstract] [Full Text] [Related]

  • 39. [Hyperlipemias and their manifestations in the rheumatological sphere].
    Rondier J, Cayla J, Roux H, Turpin G.
    Sem Hop; 1982 Aug 31; 53(14-15):813-22. PubMed ID: 194331
    [Abstract] [Full Text] [Related]

  • 40. [Clinical experimentation of clofibride. Apropos of 40 cases].
    Warembourg H, Jaillard J.
    Lille Med; 1973 Dec 31; 18(10 Suppl 5):suppl 5:1292-6. PubMed ID: 4802928
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.